MMP8
Neutrophil collagenase
As of the edition of 20 October 2026, MMP8 (neutrophil collagenase, UniProt P22894) has 3 drugs tested at it and 9 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P22894
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 25
- Disease areas
- Infections; Skin and connective tissue; Lungs and airways; Urinary and reproductive; Cancer; Heart and blood vessels; Digestive system; Immune system
- Registered trials of its drugs
- 237
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Doxycycline anhydrous | Marketed | Phase 4 | none listed |
| Rebimastat | Stopped | Phase 3 | none listed |
| CTS-1027 | Went quiet | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Engaged | 6 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Bristol Myers Squibb | Route A |
| Conatus Pharmaceuticals | Route A |
The other 6 companies at MMP8
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at MMP8, ranked, with the facts behind eachRequest access. Nothing is shown until you do.